References
- Morgensztern D, Campo MJ, Dahlberg SE, et al. Molecularly targeted therapies in non–small-cell lung cancer annual update 2014. J Thorac Oncol. 2015;10:S1–S63.
- Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143:e1S–e29S.
- Shtivelman E, Hensing T, Simon GR, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5(6):1392–1433.
- Wu X, Wu G, Yao X, et al. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review. Drug Des Devel Ther. 2016;10:699–709.
- Lemjabbar-Alaoui H, Hassan OU, Yang Y, et al. Lung cancer: biology and treatment options, Biochimica et biophysica acta. Rev Cancer. 2015;1856:189–210.
- Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e341S–e368S.
- Farhat FS, Houhou W. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol. 2013;5(4):249–270.
- Sun M, Kraus WL. From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 2015;36:25–64.
- Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18(1):206.
- Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73(13):2491–2509.
- Li C, Zhou L, He J, et al. Increased long noncoding RNA SNHG20 predicts poor prognosis in colorectal cancer. BMC Cancer. 2016;16(1):655.
- Wu J, Zhao W, Wang Z, et al. Long non‐coding RNA SNHG20 promotes the tumorigenesis of oral squamous cell carcinoma via targeting miR‐197/LIN28 axis. J Cell Mol Med. 2019;23(1):680–688.
- Seixas E, Ramalho JS, Mota LJ, et al. Bacteria and protozoa differentially modulate the expression of Rab proteins. PLoS One. 2012;7(7):e39858.
- Lu R, Johnson DL, Stewart L, et al. Rab14 regulation of claudin-2 trafficking modulates epithelial permeability and lumen morphogenesis. Mol Biol Cell. 2014;25(11):1744–1754.
- Guo B, Wang W, Zhao Z, et al. RAB14 act as oncogene and induce proliferation of gastric cancer cells via AKT signaling pathway. PLoS One. 2017;12:e170620.
- Kim EA, Kim TG, Sung EG, et al. miR-148a increases the sensitivity to cisplatin by targeting RAB14 in renal cancer cells. Int J Oncol. 2017;50(3):984–992.
- Hou R, Jiang L, Yang Z, et al. Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway. Tumor Biol. 2016;37(12):16005–16013.
- Shang J, Sun S, Zhang L, et al. miR-211 alleviates ischaemia/reperfusion-induced kidney injury by targeting TGFβR2/TGF-β/SMAD3 pathway. Bioengineered. 2020;11(1):547–557.
- Tang C, Feng W, Bao Y, et al. Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP). Bioengineered. 2021;12(1):2119–2131.
- Liu K, Zhao D, Wang D. LINC00528 regulates myocardial infarction by targeting the miR-143-3p/COX-2 axis. Bioengineered. 2020;11(1):11–18.
- Shang D, Liu Y, Zhang J, et al. Peroxisome proliferator-activated receptor γ (PPARγ) suppresses the proliferation and metastasis of patients with urothelial carcinoma after renal transplantation by inhibiting LEF1/β-catenin signaling. Bioengineered. 2020;11(1):1350–1367.
- Zhang N, Liu JF. MicroRNA (MiR)-301a-3p regulates the proliferation of esophageal squamous cells via targeting PTEN. Bioengineered. 2020;11(1):972–983.
- Chen J, Zhang K, Song H, et al. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget. 2016;7(38):62474–62489.
- Zhang D, Cao C, Liu L, et al. Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma. J Cancer. 2016;7(5):608–617.
- Li Y, Xu J, Guo Y, et al. LncRNA SNHG20 promotes the development of laryngeal squamous cell carcinoma by regulating miR-140. Eur Rev Med Pharmacol Sci. 2019;23:3401–3409.
- Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):1310.
- Wang J, Yang Y, Ma Y, et al. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother. 2020;121:109627.
- Wu X, Xiao Y, Zhou Y, et al. lncRNA SNHG20 promotes prostate cancer migration and invasion via targeting the miR-6516-5p/SCGB2A1 axis. Am J Transl Res. 2019;11:5162–5169.
- Song M, Sun M, Xia L, et al. miR-19b-3p promotes human pancreatic cancer Capan-2 cells proliferation by targeting phosphatase and tension homolog. Ann Transl Med. 2019;7(11):236.
- Jin J, Sun Z, Yang F, et al. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. Arch Biochem Biophys. 2018;645:54–60.
- Jiang T, Ye L, Han Z, et al. miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses. J Exp Clin Cancer Res. 2017;36(1):131.
- Zhang T, Liu C, Huang S, et al. A downmodulated microRNA profiling in patients with gastric cancer. Gastroenterol Res Pract. 2017;2017:1526981–1526988.
- Wei Y, Guo S, Tang J, et al. MicroRNA-19b-3p suppresses gastric cancer development by negatively regulating neuropilin-1. Cancer Cell Int. 2020;20(1):193.